P1855
P3781
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyAn Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based ChemotherapyCabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate CancerAbiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate CancerA Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic FunctionSafety Study of Continued Enzalutamide Treatment In Prostate Cancer PatientsStudy of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate CancerDovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)Effects of Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Radiation on Prostate CancerA Randomized Phase III Study - Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADTA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate CancerAbiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate CancerA Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese MenFood Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate CancerA Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase DeficiencyA Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate CancerA Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation in Healthy Adult VolunteersIMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific AntigenStudy to Evaluate CCS1477 in Advanced TumoursAbiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate CancerPhase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO)Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With DocetaxelA Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate CancerOutcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review StudyA Study of Definitive Therapy to Treat Prostate Cancer After ProstatectomyStudy of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Coralie in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel ChemotherapyAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate CancerA Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO)A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate CancerProBio: A Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate CancerARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone AcetateStudy on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerMulti-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic AdenocarcinomaA Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerStudy of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer PatientsAbiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair DefectsApalutamide, Abiraterone Acetate, and Prednisone for the Treatment of Metastatic High Risk Castration Sensitive Prostate CancerStudy of Abiraterone Acetate, Atezolizumab, Lupron, and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate CancerA Study Designed to Evaluate the Pharmacokinetic Profile of AbirateronePK and Dose Escalation and Expansion Study of DST-2970
P4844
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerAbiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyPhase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetatePhase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancerAbiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in boneOpen-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy menEffect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancerSelective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerPhase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.Abiraterone acetate for castration resistant prostate cancer.Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.Abiraterone acetate in castration-resistant prostate cancer.Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.Abiraterone acetate: redefining hormone treatment for advanced prostate cancer.Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?Abiraterone acetate, an inhibitor of adrenal androgen synthesis in "hormone refractory prostate cancer".Abiraterone acetate for prostate cancer: a new era of hormonal therapies.Abiraterone acetate is well tolerated without concomitant use of corticosteroids.Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer.A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects.Q57134814Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancerAbiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate CancerA validated liquid chromatographic-tandem mass spectroscopy method for the quantification of abiraterone acetate and abiraterone in human plasmaWords of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, BAbiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancerAbiraterone acetateWords of wisdom. Re: phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration- resistant prostate cancer commonly remains hormone drivenAbiraterone acetateRoflumilast, indacaterol maleate, and abiraterone acetateWords of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reid AH, Yap TA, et al. J Clin Oncol 2008;26:4563-71Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerAbiraterone acetate: in metastatic castration-resistant prostate cancer
P921
Q61915102-B1933C6B-D9EC-4BDB-BBA7-BFF24C3F2D0EQ61918521-6695EB19-1274-4434-BDF7-CAE359A0D48EQ61956016-D0F4C485-6D1E-4549-A209-8B0298428238Q61957427-70736712-EA00-430E-BDFA-C8B7DBB854E1Q61969203-EC8022B8-6E61-443F-8E74-25E115EEF685Q61969681-0BC5D81A-5605-47ED-B313-9ABC163AD583Q61969720-ECF3E048-51F7-4BAD-8880-FD1B3F240AFDQ61969744-98ECCDB0-45CE-4E8A-9F3C-EC7C68BAC6AAQ62025470-D0F60FD3-187B-4058-9E04-42743431C6D0Q62030698-0044EACD-AD6A-4BFF-8602-60B408700B05Q62034171-5BBF6A11-6062-4A29-BB9A-20258EE67488Q63315712-FEAC0EB0-3B0F-46E5-9980-32BE117D2F3DQ63315785-5FF1EF0C-5FCB-4119-9DE0-3EDEE1546809Q63317999-3DFFC5FD-3EE0-4B24-81AE-5F1EB7761E01Q63319280-847B4F40-9964-46B2-A167-01799B3B7687Q63321432-B839184F-332B-4845-ACBF-B2A3B4DD767FQ63334694-42294231-D78B-4ACD-A7A0-2F6A9A75E267Q63338649-D399EDA8-BB0C-41A2-85EA-7CDA1C0806E2Q63397743-B65506E1-D9CC-4AC8-9BEA-77EF8FABF30CQ63398417-DBC6C97A-3C16-4340-AFE4-9746630E1AB0Q63400932-E5F06AAE-FBF0-42D5-ADF8-404E0D48363CQ63403966-B87F13BA-A835-4B0E-B59B-42F9DC733992Q63404016-CDA18451-3207-4231-A150-C24774982B76Q63534421-97DDBA77-4D48-4A7B-90F6-072F41BB2C37Q63570999-D4DC7417-F0CC-4DC0-B5CA-C34A8C63EB4DQ63572753-A5EAA264-1CEC-47B7-9B46-A9EB2853B362Q63577932-DED1FC80-E13E-4F99-AE3E-45CC0888D436Q63578200-6837BEBD-200D-414F-9E52-DFB432C3D9EEQ63578518-381A6F14-E9EE-492D-8537-00BF1E511590Q63588139-3A8D48C9-3128-459C-BE67-82389287CBFBQ63590750-409BBC09-481E-48FD-859C-BDC4DEB3D35CQ63595572-57B4C747-CD68-46B4-AA13-E4D3EEEDAB46Q63613242-EF66D4C7-2265-46AF-A4B5-BA82C5A361A8Q63811643-C8BB35A0-EFCD-44E2-AAC1-93AD9E3FE6FFQ63811859-A6CB5A88-E23E-40E5-83FC-6622404C6D3BQ63813155-837507AA-B74F-4339-8FC4-FA7083DE28C5Q86291422-620EC6B5-4A8E-46C2-8B81-BF8AEF4D042CQ86303755-6556D6BB-64D4-4B64-B700-AB829DE89E95Q87078112-159B135D-7D27-43BE-AEB7-4E012B702A41Q87078600-469757A4-F6F6-4C80-BFDE-20E5098AA401
P4844
Q24646000-E712BE73-329F-4900-990D-BF0BD6C2AF73Q28275476-C910258B-8ADD-4BB3-9471-6FE62F5AC406Q33770362-A56A3977-B616-4019-8336-D452233273B7Q33770374-B7D12668-9D1B-4A73-B0C7-BC0D77E06A61Q34578443-F39F324F-9FA3-4B8F-9E79-4EE4360045D8Q34619574-E6D64397-B7AD-4314-B8E4-F71FC684A647Q34629038-DD814DE6-5970-439A-A958-C36E0A38333CQ34798892-F341DBBB-2BA5-49F6-9735-784A7BD3BC1FQ35256427-80C4E890-39A3-4B97-A860-E3B498BC5EBDQ35808422-43A8CC20-C09C-4A3D-A626-33C1C5DD6A61Q35996237-00A921DE-A6B1-4B9C-A34C-91F2BF71075BQ36117284-A84D4367-5C2C-40E1-9B44-43A819EB3B19Q36504117-FEDF3AC0-5F90-4212-AFA0-128C44DAB89DQ36854826-5871DC4F-E047-4874-B4C8-C52E09E6CF38Q37708308-BD2B0F77-7A86-49B2-BC26-9877A5A8A4E3Q37829693-754D3886-E3FE-484D-A067-DB55622530B0Q37962151-789A0190-92A7-4F16-B9E3-66C2F341A145Q37963173-31D89D8D-89AE-4588-9B5B-C54F66703489Q37971267-68FF939F-97AC-4B25-A0DF-6E75E66A4F5BQ37980116-5BE7A341-1B53-433F-B6E2-58F25E55E5CEQ38047794-DDDFFB32-895B-4623-9C7C-77F7CA68EE16Q39372450-074ADFBB-E13D-469B-B5E2-CA25690CB2F4Q41850941-FCA0901D-E0AA-45CB-9551-18FDD7D4D60AQ41997785-C3B5570D-3CB7-4154-9FCA-C89542B1103DQ42921826-E31509D4-266F-4748-91EC-F091936EA2EAQ42964655-CDD9EB47-AF0B-4E50-9289-17360B018AAEQ45240509-6F044CEA-1559-407F-A07E-DE2EC4F91082Q57134814-60379E24-03AB-4D0F-B551-EC67DE508183Q57136210-047D28A9-8115-4E5C-A943-19AD092C6794Q60486503-63282424-21AA-4F28-BAE8-C9ACDBA032E0Q79814923-E616E88A-7B6E-4E87-9735-08E2CB449039Q82400236-F7E9B023-8ABC-4ED7-8993-881CA80037F8Q82847589-E9EFCF9B-7872-4E91-ACF0-6162B793BAAEQ82960310-B558093D-3164-49B3-96E5-B408A39962A9Q83287705-53C7D038-BD5C-450E-AC03-12D57759C6C0Q84628177-B6E394B2-D3A2-4AA7-988D-4A6E35F3F454Q84900421-1DF6F81A-08E6-43B6-AD50-171364D04FD1Q85054649-2ED6ABDD-88A6-44A7-969E-DFB14CA2536EQ85054663-3E3FC36E-3949-4D28-B1E6-F887B4E62CCDQ85068495-1187AED2-3D71-4F63-BA3E-B495D0F44E11
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Abiraterone acetate
@vi
abirateron-acetát
@hu
abiraterone acetate
@en
octan abirateronu
@pl
type
label
Abiraterone acetate
@vi
abirateron-acetát
@hu
abiraterone acetate
@en
octan abirateronu
@pl
prefLabel
Abiraterone acetate
@vi
abirateron-acetát
@hu
abiraterone acetate
@en
octan abirateronu
@pl
P2868
P31
P486
P592
P661
P662
P683
P2017
CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4C5=CN=CC=C5)C)C
P2115
N0000182731
P231
154229-18-2
P232
P233
CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C
P234
1S/C26H33NO2/c1-17(28)29-20-10 ...... t20-,21-,23-,24-,25-,26+/m0/s1
P235
UVIQSJCZCSLXRZ-UBUQANBQSA-N
P2566
100.149.063
P274
P2892
P31
P3117
DTXSID3049043